Gui-Dong Zhu is the founder and CEO of the SparX Group. He is a 27-year veteran in pharmaceutical industry, 22 Years with various leadership responsibilities at Abbott/Abbvie, contributing to the development of one product and six candidates in different stages of clinical trials. Following the incorporation of SparX Group in 2018, Gui-Dong built sophisticated and integrated technology platforms for antibody development including the SparxNano platform for the discovery of highly potent and specific single domain antibodies and the SynMabTM platform for optimization of multi-specific antibodies. Gui-Dong also has expertise in other aspects of pharmaceutical research including structural biology, drug delivery, antibody manufacturing, and all phases of preclinical studies. Gui-Dong is author or co-author of more than one hundred publications of original papers, reviews, patents and presentations, along with over six hundred commentaries. Gui-Dong has also been an invited and plenary speaker in a number of venues both nationally and internationally.
Menu
